Skip to main content
Erschienen in: Cancer Causes & Control 4/2006

01.05.2006 | Original Paper

Survival Among Patients with Adenocarcinoma of the Pancreas: A Population-based Study (United States)

verfasst von: Rosemary D. Cress, Daixin Yin, Lisa Clarke, Richard Bold, Elizabeth A. Holly

Erschienen in: Cancer Causes & Control | Ausgabe 4/2006

Einloggen, um Zugang zu erhalten

Abstract

Objective

The purpose of the current study was to evaluate survival of patients diagnosed in California with adenocarcinoma of the pancreas by demographic and tumor-related factors.

Methods

Through the California Cancer Registry (CCR) we identified all California residents diagnosed with invasive pancreatic adenocarcinoma between 1994 and 2000. Demographic, tumor and treatment information was extracted from the CCR, and socioeconomic status (SES) was assigned based on census block group of residence.

Results

A total of 10,612 eligible patients were identified of whom 1674 (15.8%) underwent surgical resection. Patients of lower SES were less likely to undergo resection and somewhat less likely to survive. Median survival was 3.5 months for patients who were not resected and 13.3 months for those who underwent resection. Adjuvant therapy was associated with a decreased risk of death among patients who underwent resection.

Conclusions

This study is the largest population-based study to date to explore survival from pancreatic cancer among all age groups in a racially diverse population. Median survival was shorter than that reported from other series. Race/ethnicity did not have a significant effect on survival. However patients residing in poor neighborhoods were less likely to undergo resection and somewhat less likely to survive this disease.
Literatur
1.
Zurück zum Zitat Tucker T, Howe H, Weir H (1999) Certification for population-based cancer registries. J Registry Manage 26:24–27 Tucker T, Howe H, Weir H (1999) Certification for population-based cancer registries. J Registry Manage 26:24–27
2.
Zurück zum Zitat Stewart S, Glaser S, Horn-Ross P, West D (1993) SEER study of methods to classify Hispanic cancer patients (Final Report: Contract N01-CN-05224). In Edition Union City, CA: Northern California Cancer Center Stewart S, Glaser S, Horn-Ross P, West D (1993) SEER study of methods to classify Hispanic cancer patients (Final Report: Contract N01-CN-05224). In Edition Union City, CA: Northern California Cancer Center
3.
Zurück zum Zitat Kwong S, Perkins C, Morris C et al. (2001) Cancer in California: 1988–1999. In Edition Sacramento, CA: California Department of Health Services, Cancer Surveillance Section Kwong S, Perkins C, Morris C et al. (2001) Cancer in California: 1988–1999. In Edition Sacramento, CA: California Department of Health Services, Cancer Surveillance Section
4.
Zurück zum Zitat Shambaugh E, Ries L, Young J et al. (1992) SEER Extent of Disease – 1988 Codes and Coding Instructions Shambaugh E, Ries L, Young J et al. (1992) SEER Extent of Disease – 1988 Codes and Coding Instructions
5.
Zurück zum Zitat Seiffert J, ed. (1993) SEER Program: comparative staging guide for cancer, version 1.1. National Cancer Institute Seiffert J, ed. (1993) SEER Program: comparative staging guide for cancer, version 1.1. National Cancer Institute
6.
Zurück zum Zitat Young J, Roffers S, Ries L et al. (2001) SEER Summary Staging Manual – 2000. Codes and Coding Instructions, National Cancer Institute, Bethesda, MD Young J, Roffers S, Ries L et al. (2001) SEER Summary Staging Manual – 2000. Codes and Coding Instructions, National Cancer Institute, Bethesda, MD
7.
Zurück zum Zitat Percy C, Van Holten V, Muir C (eds) (1990) International Classification of Diseases for Oncology, 2nd Edition. Geneva: World Health Organization Percy C, Van Holten V, Muir C (eds) (1990) International Classification of Diseases for Oncology, 2nd Edition. Geneva: World Health Organization
8.
Zurück zum Zitat Yost K, Perkins C, Cohen R et al. (2001) Socioeconomic status and breast cancer incidence in California for different race/ethnic groups. Cancer Causes Control 12:703–711CrossRefPubMed Yost K, Perkins C, Cohen R et al. (2001) Socioeconomic status and breast cancer incidence in California for different race/ethnic groups. Cancer Causes Control 12:703–711CrossRefPubMed
9.
Zurück zum Zitat Kaplan E, Meier P (1958) Nonparametric estimation from incomplete observations. J Am Stat Assoc 53:457–481 Kaplan E, Meier P (1958) Nonparametric estimation from incomplete observations. J Am Stat Assoc 53:457–481
10.
Zurück zum Zitat Mantel N (1966) Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep 50:163–170PubMed Mantel N (1966) Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep 50:163–170PubMed
11.
Zurück zum Zitat Cox D (1972) Regression models and life tables. J R Stat Soc 34:187–202 Cox D (1972) Regression models and life tables. J R Stat Soc 34:187–202
12.
Zurück zum Zitat Lim JE, Chien MW, Earle CC (2003) Prognostic factors following curative resection for pancreatic adenocarcinoma: a population-based, linked database analysis of 396 patients. Ann Surg 237:74–85PubMed Lim JE, Chien MW, Earle CC (2003) Prognostic factors following curative resection for pancreatic adenocarcinoma: a population-based, linked database analysis of 396 patients. Ann Surg 237:74–85PubMed
13.
Zurück zum Zitat Nattinger AB, McAuliffe TL, Schapira MM (1997) Generalizability of the surveillance, epidemiology, and end results registry population: factors relevant to epidemiologic and health care research. J Clin Epidemiol 50:939–945CrossRefPubMed Nattinger AB, McAuliffe TL, Schapira MM (1997) Generalizability of the surveillance, epidemiology, and end results registry population: factors relevant to epidemiologic and health care research. J Clin Epidemiol 50:939–945CrossRefPubMed
14.
Zurück zum Zitat Warren JL, Klabunde CN, Schrag D et al. (2002) Overview of the SEER-Medicare data: content, research applications, and generalizability to the United States elderly population. Med Care 40:IV-3-18 Warren JL, Klabunde CN, Schrag D et al. (2002) Overview of the SEER-Medicare data: content, research applications, and generalizability to the United States elderly population. Med Care 40:IV-3-18
15.
Zurück zum Zitat Tsiotos GG, Farnell MB, Sarr MG (1999) Are the results of pancreatectomy for pancreatic cancer improving? World J Surg 23:913–919CrossRefPubMed Tsiotos GG, Farnell MB, Sarr MG (1999) Are the results of pancreatectomy for pancreatic cancer improving? World J Surg 23:913–919CrossRefPubMed
16.
Zurück zum Zitat Bachmann MO, Alderson D, Peters TJ et al. (2003) Influence of specialization on the management and outcome of patients with pancreatic cancer. Br J Surg 90:171–177CrossRefPubMed Bachmann MO, Alderson D, Peters TJ et al. (2003) Influence of specialization on the management and outcome of patients with pancreatic cancer. Br J Surg 90:171–177CrossRefPubMed
17.
Zurück zum Zitat Niederhuber JE, Brennan MF, Menck HR (1995) The National Cancer Data Base report on pancreatic cancer. Cancer 76:1671–1677PubMed Niederhuber JE, Brennan MF, Menck HR (1995) The National Cancer Data Base report on pancreatic cancer. Cancer 76:1671–1677PubMed
18.
Zurück zum Zitat Nitecki SS, Sarr MG, Colby TV, van Heerden JA (1995) Long-term survival after resection for ductal adenocarcinoma of the pancreas. Is it really improving? Ann Surg 221:59–66PubMed Nitecki SS, Sarr MG, Colby TV, van Heerden JA (1995) Long-term survival after resection for ductal adenocarcinoma of the pancreas. Is it really improving? Ann Surg 221:59–66PubMed
19.
Zurück zum Zitat Gudjonsson B (2002) Survival statistics gone awry: pancreatic cancer, a case in point. J Clin Gastroenterol 35:180–184CrossRefPubMed Gudjonsson B (2002) Survival statistics gone awry: pancreatic cancer, a case in point. J Clin Gastroenterol 35:180–184CrossRefPubMed
20.
Zurück zum Zitat Conlon KC, Klimstra DS, Brennan MF (1996) Long-term survival after curative resection for pancreatic ductal adenocarcinoma. Clinicopathologic analysis of 5-year survivors. Ann Surg 223:273–279PubMed Conlon KC, Klimstra DS, Brennan MF (1996) Long-term survival after curative resection for pancreatic ductal adenocarcinoma. Clinicopathologic analysis of 5-year survivors. Ann Surg 223:273–279PubMed
21.
Zurück zum Zitat Kuhlmann KF, de Castro SM, Wesseling JG et al. (2004) Surgical treatment of pancreatic adenocarcinoma; actual survival and prognostic factors in 343 patients. Eur J Cancer 40:549–558CrossRefPubMed Kuhlmann KF, de Castro SM, Wesseling JG et al. (2004) Surgical treatment of pancreatic adenocarcinoma; actual survival and prognostic factors in 343 patients. Eur J Cancer 40:549–558CrossRefPubMed
22.
Zurück zum Zitat Cleary SP, Gryfe R, Guindi M et al. (2004) Prognostic factors in resected pancreatic adenocarcinoma: analysis of actual 5-year survivors. J Am Coll Surg 198:722–731CrossRefPubMed Cleary SP, Gryfe R, Guindi M et al. (2004) Prognostic factors in resected pancreatic adenocarcinoma: analysis of actual 5-year survivors. J Am Coll Surg 198:722–731CrossRefPubMed
23.
Zurück zum Zitat Choti MA (2004) Adjuvant therapy for pancreatic cancer–the debate continues. N Engl J Med 350:1249–1251CrossRefPubMed Choti MA (2004) Adjuvant therapy for pancreatic cancer–the debate continues. N Engl J Med 350:1249–1251CrossRefPubMed
24.
Zurück zum Zitat Cress RD, Zaslavsky AM, West DW et al. (2003) Completeness of information on adjuvant therapies for colorectal cancer in population-based cancer registries. Med Care 41:1006–1012PubMed Cress RD, Zaslavsky AM, West DW et al. (2003) Completeness of information on adjuvant therapies for colorectal cancer in population-based cancer registries. Med Care 41:1006–1012PubMed
25.
Zurück zum Zitat Yeo CJ, Abrams RA, Grochow LB et al. (1997) Pancreaticoduodenectomy for pancreatic adenocarcinoma: postoperative adjuvant chemoradiation improves survival. A prospective, single-institution experience. Ann Surg 225:621–633; discussion 633–626CrossRefPubMed Yeo CJ, Abrams RA, Grochow LB et al. (1997) Pancreaticoduodenectomy for pancreatic adenocarcinoma: postoperative adjuvant chemoradiation improves survival. A prospective, single-institution experience. Ann Surg 225:621–633; discussion 633–626CrossRefPubMed
26.
Zurück zum Zitat Sohn TA, Yeo CJ, Cameron JL et al. (2000) Resected adenocarcinoma of the pancreas-616 patients: results, outcomes, and prognostic indicators. J Gastrointest Surg 4:567–579PubMed Sohn TA, Yeo CJ, Cameron JL et al. (2000) Resected adenocarcinoma of the pancreas-616 patients: results, outcomes, and prognostic indicators. J Gastrointest Surg 4:567–579PubMed
Metadaten
Titel
Survival Among Patients with Adenocarcinoma of the Pancreas: A Population-based Study (United States)
verfasst von
Rosemary D. Cress
Daixin Yin
Lisa Clarke
Richard Bold
Elizabeth A. Holly
Publikationsdatum
01.05.2006
Verlag
Kluwer Academic Publishers
Erschienen in
Cancer Causes & Control / Ausgabe 4/2006
Print ISSN: 0957-5243
Elektronische ISSN: 1573-7225
DOI
https://doi.org/10.1007/s10552-005-0539-4

Weitere Artikel der Ausgabe 4/2006

Cancer Causes & Control 4/2006 Zur Ausgabe

Special Section on Cancer and Rhythm

Tumor Suppression by the Mammalian Period Genes

Alphablocker schützt vor Miktionsproblemen nach der Biopsie

16.05.2024 alpha-1-Rezeptorantagonisten Nachrichten

Nach einer Prostatabiopsie treten häufig Probleme beim Wasserlassen auf. Ob sich das durch den periinterventionellen Einsatz von Alphablockern verhindern lässt, haben australische Mediziner im Zuge einer Metaanalyse untersucht.

Antikörper-Wirkstoff-Konjugat hält solide Tumoren in Schach

16.05.2024 Zielgerichtete Therapie Nachrichten

Trastuzumab deruxtecan scheint auch jenseits von Lungenkrebs gut gegen solide Tumoren mit HER2-Mutationen zu wirken. Dafür sprechen die Daten einer offenen Pan-Tumor-Studie.

Mammakarzinom: Senken Statine das krebsbedingte Sterberisiko?

15.05.2024 Mammakarzinom Nachrichten

Frauen mit lokalem oder metastasiertem Brustkrebs, die Statine einnehmen, haben eine niedrigere krebsspezifische Mortalität als Patientinnen, die dies nicht tun, legen neue Daten aus den USA nahe.

Labor, CT-Anthropometrie zeigen Risiko für Pankreaskrebs

13.05.2024 Pankreaskarzinom Nachrichten

Gerade bei aggressiven Malignomen wie dem duktalen Adenokarzinom des Pankreas könnte Früherkennung die Therapiechancen verbessern. Noch jedoch klafft hier eine Lücke. Ein Studienteam hat einen Weg gesucht, sie zu schließen.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.